{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:11:00Z","timestamp":1776276660168,"version":"3.50.1"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Postoperative survival benefits of neoadjuvant gemcitabine and cisplatin plus durvalumab (GCD) immunochemotherapy for biliary tract cancers, which meet the criteria for borderline resectability, remain limited. A 75-year-old male presented to our hospital with epigastric pain. Diagnostic imaging demonstrated perihilar cholangiocarcinoma invading the right hepatic artery with lymph node metastasis. The patient was diagnosed with borderline resectable perihilar cholangiocarcinoma (cT3N1M0 Stage IIIC) and treated with seven cycles of GCD immunochemotherapy. Dynamic computed tomography post-immunochemotherapy revealed that the tumor decreased in size, and arterial invasion and swollen lymph nodes had disappeared. At 6\u00a0months following immunochemotherapy initiation, the patient underwent left hepatectomy, lymph node dissection, and biliary reconstruction. Histopathology showed inflammatory cell infiltration in the bile duct mucosa without cancer cells. No lymph node metastases were detected. At 2\u00a0years postoperatively, the patient remains stable without recurrence.<\/jats:p>","DOI":"10.1093\/jscr\/rjag255","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:42:32Z","timestamp":1774010552000},"source":"Crossref","is-referenced-by-count":0,"title":["Curative resection of borderline resectable perihilar cholangiocarcinoma following neoadjuvant gemcitabine and cisplatin plus durvalumab immunochemotherapy: a case report"],"prefix":"10.1093","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5629-5691","authenticated-orcid":false,"given":"Shogo","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Surgery, Izumi City General Hospital , 4-5-1 Wakecho, Izumi 594-0073 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9619-2777","authenticated-orcid":false,"given":"Hiroshi","family":"Tsukuda","sequence":"additional","affiliation":[{"name":"Department of Oncology, Izumi City General Hospital , 4-5-1 Wakecho, Izumi 594-0073 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Surgery, Izumi City General Hospital , 4-5-1 Wakecho, Izumi 594-0073 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Oncology, Izumi City General Hospital , 4-5-1 Wakecho, Izumi 594-0073 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryugo","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Izumi City General Hospital , 4-5-1 Wakecho, Izumi 594-0073 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyotaka","family":"Yukimoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Izumi City General Hospital , 4-5-1 Wakecho, Izumi 594-0073 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Tamamori","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Izumi City General Hospital , 4-5-1 Wakecho, Izumi 594-0073 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Fumimoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Izumi City General Hospital , 4-5-1 Wakecho, Izumi 594-0073 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Hiramatsu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Izumi City General Hospital , 4-5-1 Wakecho, Izumi 594-0073 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Ohta","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology , Izumi City General Hospital, 4-5-1 Wakecho, Izumi 594-0073,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2026041513290022600_ref1","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"2026041513290022600_ref2","doi-asserted-by":"publisher","first-page":"7228","DOI":"10.1245\/s10434-025-18046-6","article-title":"Real-world single-center experience with neoadjuvant gemcitabine, cisplatin, and Durvalumab in borderline resectable cholangiocarcinoma","volume":"32","author":"Dong","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"2026041513290022600_ref3","first-page":"2017","article-title":"Common terminology criteria for adverse events (CTCAE) v5.0","author":"National Cancer Institute","year":"2017","journal-title":"CTEP"},{"key":"2026041513290022600_ref4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/archsurg.1992.01420110083017","article-title":"Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas","volume":"127","author":"Evans","year":"1992","journal-title":"Arch Surg"},{"key":"2026041513290022600_ref5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.hbpd.2018.03.003","article-title":"Assessment of clinical outcomes of advanced hilar cholangiocarcinoma","volume":"17","author":"Chen","year":"2018","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"2026041513290022600_ref6","doi-asserted-by":"publisher","first-page":"37319","DOI":"10.18632\/oncotarget.9104","article-title":"Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"2026041513290022600_ref7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.surg.2020.04.068","article-title":"How long should follow-up be continued after R0 resection of perihilar cholangiocarcinoma?","volume":"168","author":"Nakahashi","year":"2020","journal-title":"Surgery"},{"key":"2026041513290022600_ref8","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1007\/s00268-018-04883-y","article-title":"Our rationale of initiating Neoadjuvant chemotherapy for hilar cholangiocarcinoma: a proposal of criteria for \"borderline resectable\" in the field of surgery for hilar cholangiocarcinoma","volume":"43","author":"Matsuyama","year":"2019","journal-title":"World J Surg"},{"key":"2026041513290022600_ref9","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2026041513290022600_ref10","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/liv.15641","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data","volume":"43","author":"Rimini","year":"2023","journal-title":"Liver Int"},{"key":"2026041513290022600_ref11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11523-024-01044-1","article-title":"Durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer: an exploratory analysis of real-world data","volume":"19","author":"Olkus","year":"2024","journal-title":"Target Oncol"},{"key":"2026041513290022600_ref12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00432-025-06239-1","article-title":"Treatment with gemcitabine\/cisplatin and durvalumab for advanced biliary tract cancer - real-world data from a multicenter German patient population","volume":"151","author":"Gerhardt","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026041513290022600_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114199","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: a large real-life worldwide population","volume":"208","author":"Rimini","year":"2024","journal-title":"Eur J Cancer"}],"container-title":["Journal of Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jscr\/article-pdf\/2026\/4\/rjag255\/68087516\/rjag255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jscr\/article-pdf\/2026\/4\/rjag255\/68087516\/rjag255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:29:09Z","timestamp":1776274149000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jscr\/article\/doi\/10.1093\/jscr\/rjag255\/8654513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jscr\/rjag255","relation":{},"ISSN":["2042-8812"],"issn-type":[{"value":"2042-8812","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,4,1]]},"article-number":"rjag255"}}